410 related articles for article (PubMed ID: 25023394)
41. iRGD-coupled responsive fluorescent nanogel for targeted drug delivery.
Su S; Wang H; Liu X; Wu Y; Nie G
Biomaterials; 2013 Apr; 34(13):3523-33. PubMed ID: 23410678
[TBL] [Abstract][Full Text] [Related]
42. Tissue-penetrating delivery of compounds and nanoparticles into tumors.
Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E
Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669
[TBL] [Abstract][Full Text] [Related]
43. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
Li Y; He H; Jia X; Lu WL; Lou J; Wei Y
Biomaterials; 2012 May; 33(15):3899-908. PubMed ID: 22364698
[TBL] [Abstract][Full Text] [Related]
44. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals.
Zong T; Mei L; Gao H; Cai W; Zhu P; Shi K; Chen J; Wang Y; Gao F; He Q
Mol Pharm; 2014 Jul; 11(7):2346-57. PubMed ID: 24893333
[TBL] [Abstract][Full Text] [Related]
45. Tumor-penetrating iRGD peptide inhibits metastasis.
Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
[TBL] [Abstract][Full Text] [Related]
46. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
47. De novo design of a tumor-penetrating peptide.
Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E
Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901
[TBL] [Abstract][Full Text] [Related]
48. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
49. iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas.
Shi X; Ma R; Lu Y; Cheng Y; Fan X; Zou J; Zheng H; Li F; Piao JG
Biochem Biophys Res Commun; 2020 Jun; 527(1):117-123. PubMed ID: 32446354
[TBL] [Abstract][Full Text] [Related]
50. iRGD as a tumor‑penetrating peptide for cancer therapy (Review).
Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J
Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432
[TBL] [Abstract][Full Text] [Related]
51. Increased Active Tumor Targeting by An αvβ3-Targeting and Cell-Penetrating Bifunctional Peptide-Mediated Dendrimer-Based Conjugate.
Ma P; Yu H; Zhang X; Mu H; Chu Y; Ni L; Xing P; Wang Y; Sun K
Pharm Res; 2017 Jan; 34(1):121-135. PubMed ID: 27848167
[TBL] [Abstract][Full Text] [Related]
52. Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery.
Liu Y; Ji M; Wong MK; Joo KI; Wang P
Biomed Res Int; 2013; 2013():378380. PubMed ID: 23691500
[TBL] [Abstract][Full Text] [Related]
53. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
54. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
55. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
Han L; Huang R; Li J; Liu S; Huang S; Jiang C
Biomaterials; 2011 Feb; 32(4):1242-52. PubMed ID: 20971503
[TBL] [Abstract][Full Text] [Related]
56. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
[TBL] [Abstract][Full Text] [Related]
57. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
Zhang ZQ; Zhong CL; Zhao X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
[TBL] [Abstract][Full Text] [Related]
58. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
Hu FQ; Zhang YY; You J; Yuan H; Du YZ
Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
[TBL] [Abstract][Full Text] [Related]
59. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.
Kim JW; Lee HS
Int J Mol Med; 2004 Oct; 14(4):529-35. PubMed ID: 15375578
[TBL] [Abstract][Full Text] [Related]
60. Poly(ethylene glycol) versus dendrimer prodrug conjugates: influence of prodrug architecture in cellular uptake and transferrin mediated targeting.
Aher N; Banerjee S; Bhansali S; Yadav R; Shidore M; Mhaske S; Chaudhari R; Asai S; Jalota-Badhwar A; Khandare J
J Biomed Nanotechnol; 2013 May; 9(5):776-89. PubMed ID: 23802407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
